Table 3 Plasma biomarker changes from baseline (week 0) to week 16. Data presented as Mean (SD)
Biomarkers | Adjusted Means (SE)a | ||
Placebo (n = 8) | Riociguat (n = 9) | p-value | |
cGMP (nM) | 41.22 (50.2) | 198.5 (47.03) | 0.046 |
CXCL4 (ng/ml) | -7.3 (105.9) | -190.7 (99.8) | 0.23 |
sE-Selectin (ng/ml) | -2.5 (2.0) | -4.7 (1.9) | 0.45 |
VEGF (pg/ml) | -34.7 (10.1) | -29.8 (9.5) | 0.73 |
sFLT1 (pg/ml) | -218.0 (211.8) | -220.5 (183.2) | 0.99 |
tPA (ng/ml) | -0.5 (0.5) | -1.2 (0.5) | 0.32 |
bFGF (pg/ml) | -0.03 (0.29) | 0.20 (0.28) | 0.58 |
sICAM1 (ng/ml) | -39.2 (50.2) | 70.5 (47.3) | 0.14 |
VCAM1 (ng/ml) | -3.4 (11.0) | 10.3 (10.4) | 0.39 |
PINP (pg/ml) | -6.6 (11.0) | 7.1 (10.3) | 0.38 |
MMP12 (ng/ml) | 0.12 (0.14) | -0.09 (0.13) | 0.31 |
Endostatin (ng/ml) | -96.8 (132.2) | -299.0 (124.5) | 0.29 |